Radiology, Interventional Radiology and Radiotherapy in Cancer: What's New?

A special issue of Tomography (ISSN 2379-139X).

Deadline for manuscript submissions: 31 March 2025 | Viewed by 1403

Special Issue Editor


E-Mail Website
Guest Editor
Radiology Unit, Buon Consiglio Fatebenefratelli Hospital, 80123 Naples, Italy
Interests: melanoma; sarcoma; thyroid cancer; head and neck cancer; lymphoma; immunotherapy; lung cancer; computed tomography imaging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The diagnosis and management of malignancy is now in the domain of the multi-disciplinary team;  radiology, Interventional Radiology (IR) and radiotherapy (also called radiation therapy) play a prominent role in this environment.

In recent years, significant advances in screening, diagnosis and treatment have improved the cure rate for some cancer patients. Cancer radiology will play an even more important role in the future. At the same time, combined with the use of artificial intelligence, deep learning will bring new development opportunities for cancer radiology.

This Special Issue intends to provide an overview of the development of the latest research on radiology, interventional radiology and radiotherapy for cancer. We encourage researchers to submit original studies, reviews, communications, case studies, and a series of new frontiers in the diagnosis, treatment, and management of cancer and oncology.

Dr. Fabio Sandomenico
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tomography is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • computed tomography
  • ultrasound
  • contrast-enhanced ultrasound
  • magnetic resonance imaging
  • radiotherapy
  • interventional radiology
  • cancer therapy
  • immunotherapy
  • radiomics
  • artificial intelligence in radiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 1720 KiB  
Article
Assessment of Psoas Muscle Index in Middle-Aged Type 2 Diabetes Patients: Impact of Insulin Therapy on Sarcopenia
by Ismail Taskent, Bunyamin Ece and Sonay Aydin
Tomography 2024, 10(7), 1054-1063; https://doi.org/10.3390/tomography10070079 - 10 Jul 2024
Viewed by 933
Abstract
Objective: Sarcopenia, characterized by progressive skeletal muscle loss, poses significant health risks, including physical impairment and mortality. The relationship between sarcopenia and insulin resistance suggests insulin therapy’s potential in preserving muscle mass, particularly in Type 2 diabetes mellitus (T2DM) patients. This study aims [...] Read more.
Objective: Sarcopenia, characterized by progressive skeletal muscle loss, poses significant health risks, including physical impairment and mortality. The relationship between sarcopenia and insulin resistance suggests insulin therapy’s potential in preserving muscle mass, particularly in Type 2 diabetes mellitus (T2DM) patients. This study aims to evaluate the Psoas Muscle Index (PMI) via computed tomography (CT) in middle-aged T2DM patients on insulin therapy versus oral antidiabetic drugs (OAD) and controls. Methods: This retrospective study included 107 middle-aged T2DM patients undergoing non-contrast CT scans and 58 age-matched controls. CT images were analyzed to calculate PMI. Statistical analysis included Chi-square tests, independent samples t-tests, Mann–Whitney U tests, and correlation analyses. Results: Insulin-treated patients exhibited higher PMI than OAD users (p < 0.001), while OAD users had lower PMI than controls (p < 0.001). No significant difference was found between insulin-treated patients and controls (p = 0.616). Negative correlations were observed between T2DM duration/age and PMI across all groups, with a positive correlation between T2DM duration and BMI observed in the OAD group. Conclusions: Insulin therapy in T2DM patients, regardless of age or disease duration, positively impacts muscle mass, highlighting its potential in preserving muscular health and advocating for tailored treatment strategies in T2DM management. Full article
Show Figures

Figure 1

Back to TopTop